JP2651043B2 - ジフェニルメチルピペラジン誘導体 - Google Patents

ジフェニルメチルピペラジン誘導体

Info

Publication number
JP2651043B2
JP2651043B2 JP2182095A JP18209590A JP2651043B2 JP 2651043 B2 JP2651043 B2 JP 2651043B2 JP 2182095 A JP2182095 A JP 2182095A JP 18209590 A JP18209590 A JP 18209590A JP 2651043 B2 JP2651043 B2 JP 2651043B2
Authority
JP
Japan
Prior art keywords
myocardial infarction
compound
formula
diphenylmethylpiperazine
necrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2182095A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0469377A (ja
Inventor
昇 金子
詢 武石
立志 大澤
功司 秋元
英男 太田
達雄 中島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Brewery Co Ltd
Original Assignee
Kirin Brewery Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2182095A priority Critical patent/JP2651043B2/ja
Application filed by Kirin Brewery Co Ltd filed Critical Kirin Brewery Co Ltd
Priority to RU9192016555A priority patent/RU2091379C1/ru
Priority to US07/958,366 priority patent/US5304558A/en
Priority to CA002087032A priority patent/CA2087032C/en
Priority to AU82125/91A priority patent/AU8212591A/en
Priority to DE69104615T priority patent/DE69104615T2/de
Priority to EP91912316A priority patent/EP0541802B1/en
Priority to PCT/JP1991/000924 priority patent/WO1992000962A1/ja
Priority to ZA915366A priority patent/ZA915366B/xx
Priority to CN91105588A priority patent/CN1037840C/zh
Priority to AT91912316T priority patent/ATE112764T1/de
Priority to TW080106989A priority patent/TW198717B/zh
Publication of JPH0469377A publication Critical patent/JPH0469377A/ja
Application granted granted Critical
Publication of JP2651043B2 publication Critical patent/JP2651043B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2182095A 1990-07-10 1990-07-10 ジフェニルメチルピペラジン誘導体 Expired - Lifetime JP2651043B2 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2182095A JP2651043B2 (ja) 1990-07-10 1990-07-10 ジフェニルメチルピペラジン誘導体
ZA915366A ZA915366B (en) 1990-07-10 1991-07-10 Diphenylmethyl piperazine derivatives
CA002087032A CA2087032C (en) 1990-07-10 1991-07-10 Diphenylmethyl piperazine derivatives
AU82125/91A AU8212591A (en) 1990-07-10 1991-07-10 Diphenylmethylpiperazine derivative
DE69104615T DE69104615T2 (de) 1990-07-10 1991-07-10 Diphenylpiperazinderivat.
EP91912316A EP0541802B1 (en) 1990-07-10 1991-07-10 Diphenylmethylpiperazine derivative
RU9192016555A RU2091379C1 (ru) 1990-07-10 1991-07-10 Дифенилметилпиперазиновые производные или их фармацевтически приемлемая соль
US07/958,366 US5304558A (en) 1990-07-10 1991-07-10 Diphenylmethyl piperazine derivatives
CN91105588A CN1037840C (zh) 1990-07-10 1991-07-10 二苯甲基哌嗪衍生物的制备方法
AT91912316T ATE112764T1 (de) 1990-07-10 1991-07-10 Diphenylpiperazinderivat.
PCT/JP1991/000924 WO1992000962A1 (en) 1990-07-10 1991-07-10 Diphenylmethylpiperazine derivative
TW080106989A TW198717B (enExample) 1990-07-10 1991-09-03

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2182095A JP2651043B2 (ja) 1990-07-10 1990-07-10 ジフェニルメチルピペラジン誘導体

Publications (2)

Publication Number Publication Date
JPH0469377A JPH0469377A (ja) 1992-03-04
JP2651043B2 true JP2651043B2 (ja) 1997-09-10

Family

ID=16112265

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2182095A Expired - Lifetime JP2651043B2 (ja) 1990-07-10 1990-07-10 ジフェニルメチルピペラジン誘導体

Country Status (12)

Country Link
US (1) US5304558A (enExample)
EP (1) EP0541802B1 (enExample)
JP (1) JP2651043B2 (enExample)
CN (1) CN1037840C (enExample)
AT (1) ATE112764T1 (enExample)
AU (1) AU8212591A (enExample)
CA (1) CA2087032C (enExample)
DE (1) DE69104615T2 (enExample)
RU (1) RU2091379C1 (enExample)
TW (1) TW198717B (enExample)
WO (1) WO1992000962A1 (enExample)
ZA (1) ZA915366B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013099048A1 (ja) 2011-12-27 2013-07-04 株式会社アエタスファルマ ジフェニルメチルピペラジン誘導体、及びそれを用いた医薬組成物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2144669A1 (en) * 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
US5658963A (en) * 1995-02-02 1997-08-19 Bisco, Inc. One-component primer/bonding-resin systems
CA2385996C (en) 1999-09-30 2008-02-12 Noboru Kaneko Anticancer agents
AU2001239469A1 (en) * 2000-03-31 2001-10-08 Pfizer Products Inc. Novel piperazine derivatives
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
AU2002326823B2 (en) * 2001-09-06 2005-12-15 Merck Sharp & Dohme Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP6021616B2 (ja) * 2012-12-04 2016-11-09 株式会社アエタスファルマ ３−ピペラジニル−１−ピペリジニル−プロパン誘導体及びそれを含有してなる医薬組成物
KR102257892B1 (ko) 2014-11-26 2021-05-28 삼성전자주식회사 개선된 ｎｆｃ 안테나 및 그 안테나를 갖는 전자 장치

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR65270B (en) * 1978-10-10 1980-07-31 Fujisawa Pharmaceutical Co Isatin derivatives and processes for the preparation thereof
DE3536797A1 (de) * 1985-10-16 1987-04-16 Studiengesellschaft Kohle Mbh Verfahren zur herstellung von halogen-magnesium-alanat und dessen verwendung
JPS62192381A (ja) * 1986-02-14 1987-08-22 サンド・アクチエンゲゼルシヤフト プリン誘導体類、その製造方法およびそれらを含有する医薬品
NL8700245A (nl) * 1986-02-14 1987-09-01 Sandoz Ag Purinederivaten, werkwijzen voor hun bereiding en geneesmiddelen die deze derivaten bevatten.
US4885300A (en) * 1988-03-03 1989-12-05 Ortho Pharmaceutical Corporation 4-Substituted pyrazolo[3,4-D]pyrimidine derivatives
US5215987A (en) * 1990-04-23 1993-06-01 Ortho Pharmaceutical Corporation Substituted benzhydryl 2-hydroxypropyl piperazine derivatives

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013099048A1 (ja) 2011-12-27 2013-07-04 株式会社アエタスファルマ ジフェニルメチルピペラジン誘導体、及びそれを用いた医薬組成物
KR20140114339A (ko) 2011-12-27 2014-09-26 가부시키가이샤 아에타스 파루마 디페닐메틸피페라진 유도체, 및 그것을 사용한 의약 조성물
US9073861B2 (en) 2011-12-27 2015-07-07 Aetas Pharma Co., Ltd. Diphenylmethyl piperazine derivative and pharmaceutical composition using same
EP3091001A1 (en) 2011-12-27 2016-11-09 Aetas Pharma Co. Ltd. Diphenylmethyl piperazine derivative and pharmaceutical composition using same
KR101963724B1 (ko) 2011-12-27 2019-03-29 가부시키가이샤 아에타스 파루마 디페닐메틸피페라진 유도체, 및 그것을 사용한 의약 조성물

Also Published As

Publication number Publication date
WO1992000962A1 (en) 1992-01-23
US5304558A (en) 1994-04-19
CA2087032A1 (en) 1992-01-11
DE69104615T2 (de) 1995-03-23
ZA915366B (en) 1992-04-29
EP0541802A4 (en) 1993-05-26
AU8212591A (en) 1992-02-04
DE69104615D1 (de) 1994-11-17
ATE112764T1 (de) 1994-10-15
EP0541802B1 (en) 1994-10-12
RU2091379C1 (ru) 1997-09-27
CN1037840C (zh) 1998-03-25
CA2087032C (en) 1999-06-15
TW198717B (enExample) 1993-01-21
JPH0469377A (ja) 1992-03-04
CN1058963A (zh) 1992-02-26
EP0541802A1 (en) 1993-05-19

Similar Documents

Publication Publication Date Title
JP2651043B2 (ja) ジフェニルメチルピペラジン誘導体
JP2703408B2 (ja) １，４‐ベンゾチアゼピン誘導体
EP0424525B1 (en) Novel amines and their use
JPWO1999020620A1 (ja) イソキノリン誘導体及び医薬
JPH04217977A (ja) 新規なベンゾオキサジン及びベンゾチアジン誘導体及びその製造方法
JPS6230780A (ja) １，７−ナフチリジン誘導体及びこれを含有する薬剤
US5326772A (en) Diaryl compounds for their use
JP3093419B2 (ja) １，４‐ベンゾチアゼピン誘導体
KR900003277B1 (ko) 피페라진 유도체의 제조방법
US5225558A (en) 2-amino-5-cyano-1,4-dihydropyridines, and their use in medicaments
KR870001681B1 (ko) 히단토인 유도체의 제조방법
JPS6256474A (ja) ジヒドロピリジン−２−ヒドロキシアミン類
US4365064A (en) 1,2,4-Oxadiazolin-5-one derivatives, process for their preparation and pharmaceutical compositions containing them
JP2834506B2 (ja) 新規チエニルオキシ‐アルキルアミン誘導体、その製法及びこの化合物を含有する医薬
HU207511B (en) Process for producing pirimidinium derivatives, nonionic formes of them and pharmaceutical compositions containing them
US4980351A (en) 3-aminopropoxyaryl derivatives having cardiotonic and antihypertensive use and compositions thereof
US4338320A (en) Esters of 6'-hydroxycinchonine, and a method of treating arrythmia with them
JPH02258749A (ja) ポリヒドロキシベンジルオキシプロパノールアミン
JP3049284B2 (ja) ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤
JP3215676B2 (ja) ピペリジン誘導体
JP2825643B2 (ja) 新規アリールオキシーアルキルアミン、その製法及びこれを含有する心臓循環系疾患治療用の医薬品
US6706732B1 (en) Nasal preparation of guanidinoimino quinoline derivatives
EP0347733A1 (en) Optically active hydantoin derivatives
JPH03145464A (ja) 光学活性１，４―ジヒドロピリジン誘導体
KR820001447B1 (ko) 3-인돌릴-3급 부틸아미노프로판올의 제조방법

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090516

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100516

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100516

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110516

Year of fee payment: 14

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110516

Year of fee payment: 14